CY1111571T1 - Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων - Google Patents

Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων

Info

Publication number
CY1111571T1
CY1111571T1 CY20111100581T CY111100581T CY1111571T1 CY 1111571 T1 CY1111571 T1 CY 1111571T1 CY 20111100581 T CY20111100581 T CY 20111100581T CY 111100581 T CY111100581 T CY 111100581T CY 1111571 T1 CY1111571 T1 CY 1111571T1
Authority
CY
Cyprus
Prior art keywords
treatment
bacterial infections
azroneonam
inhalated
prevention
Prior art date
Application number
CY20111100581T
Other languages
Greek (el)
English (en)
Inventor
Alan Bruce Montgomery
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22980480&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111571(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of CY1111571T1 publication Critical patent/CY1111571T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
CY20111100581T 2000-12-27 2011-06-16 Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων CY1111571T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25842300P 2000-12-27 2000-12-27
EP01991523A EP1353647B1 (en) 2000-12-27 2001-12-20 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections

Publications (1)

Publication Number Publication Date
CY1111571T1 true CY1111571T1 (el) 2014-04-09

Family

ID=22980480

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100581T CY1111571T1 (el) 2000-12-27 2011-06-16 Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων
CY2011012C CY2011012I1 (el) 2000-12-27 2011-08-22 Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2011012C CY2011012I1 (el) 2000-12-27 2011-08-22 Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων

Country Status (19)

Country Link
US (6) US6660249B2 (enExample)
EP (2) EP2301524B1 (enExample)
JP (1) JP4646489B2 (enExample)
AT (1) ATE502623T1 (enExample)
AU (1) AU2002231244B2 (enExample)
BE (1) BE2011C029I2 (enExample)
BR (1) BRPI0116757B8 (enExample)
CA (2) CA2433280C (enExample)
CY (2) CY1111571T1 (enExample)
DE (2) DE60144291D1 (enExample)
DK (2) DK2301524T3 (enExample)
ES (2) ES2406405T3 (enExample)
FR (1) FR11C0030I2 (enExample)
IL (3) IL156596A0 (enExample)
LU (1) LU91851I2 (enExample)
NL (1) NL300492I2 (enExample)
NO (3) NO329643B1 (enExample)
PT (2) PT2301524E (enExample)
WO (1) WO2002051356A2 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
DK2301524T3 (da) 2000-12-27 2013-07-15 Gilead Sciences Inc Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US20030133925A1 (en) * 2001-09-28 2003-07-17 Shawar Ribhi M. Monobactam compositions and methods of use thereof
AU2003230600B2 (en) * 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
MXPA05001486A (es) 2002-08-05 2006-05-25 Teva Gyogyszergyar Reszvenytar Preparacion de aztreonam.
WO2004052333A1 (en) * 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
JP2006522634A (ja) * 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US7452991B2 (en) 2003-05-15 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Aztreonam β polymorph with very low residual solvent content
WO2004103478A1 (en) * 2003-05-20 2004-12-02 Collins James F Ophthalmic drug delivery system
BRPI0411691A (pt) * 2003-07-02 2006-12-26 Teva Gyogyszergyar Reszvenytar l-lisina de aztreonam e seus métodos de preparação
AU2014271333B2 (en) * 2003-07-03 2016-10-27 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2004257632C1 (en) * 2003-07-03 2010-04-15 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7452523B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
WO2006122253A1 (en) 2005-05-09 2006-11-16 Sicor, Inc. Process for making aztreonam
US20080107723A1 (en) * 2006-09-28 2008-05-08 Perkins Walter R Methods of Treating Pulmonary Distress
HUP0700007A2 (en) * 2007-01-08 2008-10-28 Asthma Rehabilitacios Ct Kft Device and process for producing of natrium chloride aerosol for the disorders of the respiratory system
CN101715349B (zh) * 2007-05-08 2012-07-18 美国Rq生物科技有限公司 治疗革兰氏阴性细菌感染的治疗组合物及方法
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
WO2009045706A1 (en) * 2007-10-01 2009-04-09 Gilead Sciences, Inc. Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of life in lung diseases
RU2527894C2 (ru) * 2007-11-27 2014-09-10 Альгифарма ИПР АС Использование альгинатных олигомеров в борьбе с биопленками
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
JP5671001B2 (ja) 2009-03-26 2015-02-18 パルマトリックス,インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
RU2582938C2 (ru) * 2009-06-03 2016-04-27 АльгиФарма АС Альгинатные олигомеры для применения в преодолении множественной лекарственной устойчивости у бактерий
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
EP4008326A1 (en) 2010-09-29 2022-06-08 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
PT2621488T (pt) 2010-09-29 2019-02-12 Pulmatrix Operating Co Inc Pós secos catiónicos
EP2804589A1 (en) * 2012-01-16 2014-11-26 Mahmut Bilgic Pharmaceutical formulations comprising aztreonam
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
EP2978434A4 (en) * 2013-03-28 2016-08-17 Pharmacaribe Llc COMPOSITIONS, FORMULATIONS AND METHODS FOR BIO-ALIGNING THE PH-VALUE OF A STERILE ISOTONIC SALT SOLUTION AND HYPERTONIC SALT SOLUTIONS
KR20150135328A (ko) 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
CN104784159A (zh) * 2015-04-15 2015-07-22 苏州惠仁生物科技有限公司 氨曲南粉雾剂的制备方法
KR102295739B1 (ko) 2016-05-03 2021-08-30 뉴마 레스퍼러토리 인코포레이티드 유체들의 폐기관계로의 전달을 위한 액적 전달 디바이스 및 사용 방법
US11285274B2 (en) 2016-05-03 2022-03-29 Pneuma Respiratory, Inc. Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device
WO2017192773A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency
WO2017192782A1 (en) * 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment
EP4624054A3 (en) 2016-05-03 2025-11-19 Pneuma Respiratory, Inc. Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device
WO2018213834A1 (en) 2017-05-19 2018-11-22 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
KR102643190B1 (ko) 2017-06-10 2024-03-04 아이노비아 인코포레이티드 유체를 취급하기 위한, 그리고 눈에 유체를 전달하기 위한 디바이스들
CN118203735A (zh) 2017-10-04 2024-06-18 精呼吸股份有限公司 电子呼吸致动式直线型液滴输送装置及其使用方法
EP3697481B1 (en) 2017-10-17 2024-05-22 Pneuma Respiratory, Inc. Nasal drug delivery apparatus and methods of use
CA3082192A1 (en) 2017-11-08 2019-05-16 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device with small volume ampoule and methods of use
CN110898040B (zh) * 2018-09-18 2022-05-17 北京盈科瑞创新药物研究有限公司 一种吸入用氨曲南溶液用冻干粉及其制备方法
US12208061B2 (en) * 2019-02-28 2025-01-28 Exorao Life Science S.R.L. Sterile aztreonam package
US12691236B2 (en) 2019-05-09 2026-07-28 Pneuma Respiratory, Inc. Ultrasonic breath actuated respiratory droplet delivery device and methods of use
CN114206421A (zh) 2019-06-27 2022-03-18 精呼吸股份有限公司 小液滴经由电子呼吸致动液滴输送装置到呼吸系统的输送
WO2021119513A1 (en) 2019-12-11 2021-06-17 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
CN111647537B (zh) * 2020-06-18 2022-04-26 浙江工业大学 一种耐盐辣椒素降解菌、应用及餐厨垃圾处理方法
WO2022271848A1 (en) 2021-06-22 2022-12-29 Pneuma Respiratory, Inc. Droplet delivery device with push ejection
CN119768202A (zh) 2022-07-18 2025-04-04 精呼吸股份有限公司 小步长高分辨率气溶胶生成系统及方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126A (en) * 1852-07-13 Marcus r
US610824A (en) * 1898-09-13 Sleigh attachment for vehicles
US572801A (en) * 1896-12-08 Telephone-exchange
US673739A (en) * 1900-09-19 1901-05-07 Frank B Stearns Driving mechanism for vehicles.
US775670A (en) * 1904-08-17 1904-11-22 Thomas F Whittelsey Air-brake safety device.
US946838A (en) * 1909-08-17 1910-01-18 George Dawson Tempering compound.
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) * 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en) 1980-12-05 1987-06-16 Takeda Chemical Industries, Ltd. 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4529698A (en) * 1981-01-19 1985-07-16 E. R. Squibb & Sons, Inc. Process for preparing a 2-oxo-1-azetidinesulfonic acid salt
US4386034A (en) * 1981-02-02 1983-05-31 E. R. Squibb & Sons, Inc. Sulfamated amino acid amides
US4625022A (en) * 1981-02-02 1986-11-25 E. R. Squibb & Sons, Inc. Process for preparing (s)-3-amino-2-oxo-1-azetidinesulfonic acid salts
US4572801A (en) 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
CA1181075A (en) 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
US4946838A (en) 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
US4752469A (en) * 1984-01-09 1988-06-21 E. R. Squibb & Sons, Inc. Potentiators of beta-lactam antibiotics
US4826973A (en) * 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) * 1986-07-11 1989-12-26 Beckman Instruments, Inc. Sample handling system
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
US5194604A (en) * 1990-06-29 1993-03-16 E. R. Squibb & Sons, Inc. Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
CA2181164C (en) * 1994-01-14 2008-01-08 Arnold Horwitz Anti-gram-positive bacterial methods and materials
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
WO1998009990A1 (en) 1996-09-04 1998-03-12 Takara Shuzo Co., Ltd. Fungal antigens and process for producing the same
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
CA2410694A1 (en) 1998-06-16 1999-12-16 Serge Dea Porcine reproductive and respiratory syndrome virus (prrsv) dna vaccines
CA2514899A1 (en) 1998-08-31 2000-03-09 Biogen, Inc. Method of modulating memory effector t-cells and compositions
CN1348377A (zh) * 1998-12-17 2002-05-08 希龙公司 用气溶胶化的抗生素治疗严重慢性支气管炎(支气管扩张症)的方法
AU782493B2 (en) 1999-06-01 2005-08-04 Curis, Inc. Polymer conjugates of hedgehog proteins and uses
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
DE60025019T2 (de) * 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DK2301524T3 (da) 2000-12-27 2013-07-15 Gilead Sciences Inc Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
WO2003031163A2 (en) * 2001-10-08 2003-04-17 California Institute Of Technology Microfabricated lenses, methods of manufacture thereof, and applications therefor
JP2005508220A (ja) 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
AU2003230600B2 (en) 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
EP1417958A1 (en) 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
WO2004052333A1 (en) 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
BRPI0411691A (pt) 2003-07-02 2006-12-26 Teva Gyogyszergyar Reszvenytar l-lisina de aztreonam e seus métodos de preparação
WO2009045706A1 (en) 2007-10-01 2009-04-09 Gilead Sciences, Inc. Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of life in lung diseases

Also Published As

Publication number Publication date
DE122011100043I1 (de) 2011-12-15
US6660249B2 (en) 2003-12-09
CY2011012I2 (el) 2014-04-09
FR11C0030I1 (enExample) 2011-09-23
US20170296517A1 (en) 2017-10-19
JP4646489B2 (ja) 2011-03-09
BR0116757B1 (pt) 2014-02-04
CA2433280A1 (en) 2002-07-04
BR0116757A (pt) 2003-11-04
EP1353647A4 (en) 2007-05-09
US20030055034A1 (en) 2003-03-20
DE60144291D1 (de) 2011-05-05
NO20101377L (no) 2003-08-26
IL221036A0 (en) 2012-08-30
BRPI0116757B8 (pt) 2021-05-25
EP2301524B1 (en) 2013-04-24
NO2011001I2 (no) 2013-05-27
ES2360692T3 (es) 2011-06-08
CY2011012I1 (el) 2014-04-09
CA2708703A1 (en) 2002-07-04
WO2002051356A2 (en) 2002-07-04
CA2433280C (en) 2010-09-21
PT1353647E (pt) 2011-05-24
LU91851I2 (fr) 2011-10-03
NO20032946D0 (no) 2003-06-26
LU91851I9 (enExample) 2019-01-03
US20140037735A1 (en) 2014-02-06
US7208141B2 (en) 2007-04-24
FR11C0030I2 (fr) 2012-03-16
PT2301524E (pt) 2013-07-10
CA2708703C (en) 2012-12-04
US20080050439A1 (en) 2008-02-28
NO2011001I1 (no) 2011-02-07
EP1353647A2 (en) 2003-10-22
US20120093890A1 (en) 2012-04-19
AU2002231244B2 (en) 2006-06-29
WO2002051356A3 (en) 2002-10-31
ATE502623T1 (de) 2011-04-15
US9533000B2 (en) 2017-01-03
NO329643B1 (no) 2010-11-22
BE2011C029I2 (enExample) 2021-07-26
ES2406405T3 (es) 2013-06-06
NL300492I2 (nl) 2017-11-02
IL156596A (en) 2012-07-31
EP2301524A1 (en) 2011-03-30
JP2004516302A (ja) 2004-06-03
DK1353647T3 (da) 2011-06-14
US20050129623A1 (en) 2005-06-16
DK2301524T3 (da) 2013-07-15
IL156596A0 (en) 2004-01-04
NO20032946L (no) 2003-08-26
EP1353647B1 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
NO20032946L (no) Inhalerbar aztreonam for behandling og forhindring av pulmonale bakterielleinfeksjoner
CY1114621T1 (el) Συνταγοποιηση εισπνευσιμης λυσινικης αζτρεοναμης για τη θεραπευτικη αγωγη και προληψη πνευμονικων βακτηριακων μολυνσεων
CY1111061T1 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
NO20024772D0 (no) Percyquinnin, fremgangsmåte for dets fremstilling og dets anvendelse som et legemiddel
WO2008105515A1 (ja) 新規なヒドロキサム酸誘導体
ATE556061T1 (de) Therapeutisches oder prophylaktisches mittel gegen multiple sklerose
JP2017510580A5 (enExample)
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
EA200301305A1 (ru) Оптимизированный препарат тобрамицина для аэрозолизации
WO2003097574A3 (en) Aminoalkoxy-functional chalcones
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
ES2133722T3 (es) Utilizacion de dextranos simples o conjugados para la fabricacion de un medicamento para prevenir o reducir el riesgo de infeccion de germenes patogenos bacterianos.
CY1114144T1 (el) Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων
EP1604660A4 (en) MEDICINAL COMPOSITION FOR TREATING STAPHYLOCOCUS AUREUS INFECTION RESISTANT TO MEDICAMENTS
ATE497761T1 (de) Therapeutisches oder prophylaktisches mittel gegen leukämie
UY26814A1 (es) Método y composición
EE05090B1 (et) Tsklipostiinihend kasutamiseks diabeedivastase ravimina, seda sisaldav farmatseutiline preparaat,hendi ja preparaadi valmistamine ning selleks vajalik mikroorganism
AR040420A1 (es) Aztreonam inhalable para el tratamiento y la prevencion de infecciones bacterianas pulmonares
AU2002360218A1 (en) A METHOD OF TREATING BACTERIAL INFECTIONS USING GEMIFLOXACIN OR A SALT THEREOF AND A Beta -LACTAM ANTIBIOTIC
TNSN06114A1 (fr) Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus
WO2004056306A3 (de) Verwendung von l-dopa, seiner derivate und diese verbindungen enthaltender arzneimittel zur prophylaxe psychotischer erkrankungen
NO20035102D0 (no) Anvendelse av en gatran for fremstilling av et medikament for behandling avlunge fibrose
AR054219A1 (es) Formulacion de lisinato de aztreonam inhalable para el tratamiento y la prevencion de infecciones pulmonares bacteriales
HK1092736A1 (zh) 持续释放口服吗多明合成物用於治疗动脉粥状硬化